



Gilteritinib (Xospata®)

Akute Myeloische Leukämie (AML) » rezidiert/refraktär » FLT3 mutiert

Empfehlungen der Fachgesellschaft zum Einsatz neuer Arzneimittel

Herausgeber

DGHO Deutsche Gesellschaft für Hämatologie und
Medizinische Onkologie e.V.
Alexanderplatz 1
10178 Berlin

Geschäftsführender Vorsitzender: Prof. Dr. med. Hermann Einsele

Telefon: +49 (0)30 27 87 60 89 - 0
Telefax: +49 (0)30 27 87 60 89 - 18

info@dgho.de
www.dgho.de

Ansprechpartner

Prof. Dr. med. Bernhard Wörmann
Medizinischer Leiter

Quelle

www.onkopedia.com

Die Empfehlungen der DGHO für die Diagnostik und Therapie hämatologischer und onkologischer Erkrankungen entbinden die verantwortliche Ärztin / den verantwortlichen Arzt nicht davon, notwendige Diagnostik, Indikationen, Kontraindikationen und Dosierungen im Einzelfall zu überprüfen! Die DGHO übernimmt für Empfehlungen keine Gewähr.

Inhaltsverzeichnis

1 Gilteritinib, AML, relapsed/refractory, FLT3mut	2
--	----------


Gilteritinib (Xospata®)

Dokument: Fact Sheet

Spezifizierung: Akute Myeloische Leukämie (AML) » rezidiert/refraktär » FLT3 mutiert

Stand: Januar 2022

1 Gilteritinib, AML, relapsed/refractory, FLT3mut

Gilteritinib, AML, relapsed/refractory, FLT3mut																																																																
	Facts	Appraisal	EU Approval 2019																																																													
<table border="1" style="width: 100%; border-collapse: collapse;"> <thead> <tr> <th style="text-align: left;">Parameter</th> <th style="text-align: left;">Results¹⁴</th> <th style="text-align: left;">HR¹⁵</th> <th style="text-align: left;">p value</th> </tr> </thead> <tbody> <tr> <td>RR²</td> <td>10.5¹⁹ vs 21.1¹⁹</td> <td></td> <td>n.s.¹⁶</td> </tr> <tr> <td>OS⁵</td> <td>5.6 vs 9.3</td> <td>0.64</td> <td>p < 0.001</td> </tr> <tr> <td>EFS⁸</td> <td>0.7 vs 2.8</td> <td>0.79</td> <td>n.s.¹⁶</td> </tr> </tbody> </table>	Parameter	Results ¹⁴	HR ¹⁵	p value	RR ²	10.5 ¹⁹ vs 21.1 ¹⁹		n.s. ¹⁶	OS ⁵	5.6 vs 9.3	0.64	p < 0.001	EFS ⁸	0.7 vs 2.8	0.79	n.s. ¹⁶	<table border="1" style="width: 100%; border-collapse: collapse;"> <thead> <tr> <th style="text-align: left;">Evidence (LoE)</th> <th>5</th> <th>4</th> <th>3b</th> <th>3a</th> <th>2c</th> <th>2b</th> <th>2a</th> <th>1b</th> <th>1a</th> </tr> </thead> <tbody> <tr> <td></td> <td style="background-color: #cccccc;"></td> <td style="background-color: #cccccc;"></td> <td style="background-color: #cccccc;"></td> <td style="background-color: #cccccc;"></td> <td style="background-color: #cccccc;"></td> <td style="background-color: #cccccc;"></td> <td style="background-color: #cccccc;"></td> <td style="background-color: black;"></td> <td style="background-color: #cccccc;"></td> </tr> </tbody> </table> <table border="1" style="width: 100%; border-collapse: collapse;"> <thead> <tr> <th style="text-align: left;">Clinical benefit (ESMO MCBS)</th> <th>1</th> <th>2</th> <th>3</th> <th>4</th> <th>5</th> </tr> </thead> <tbody> <tr> <td></td> <td style="background-color: #cccccc;"></td> <td style="background-color: #cccccc;"></td> <td style="background-color: #cccccc;"></td> <td style="background-color: #cccccc;"></td> <td style="background-color: #cccccc;"></td> </tr> </tbody> </table> <p> ■ curative ■ non-curative </p>	Evidence (LoE)	5	4	3b	3a	2c	2b	2a	1b	1a											Clinical benefit (ESMO MCBS)	1	2	3	4	5							<table border="1" style="width: 100%; border-collapse: collapse;"> <thead> <tr> <th style="text-align: left;">Additional benefit (G-BA)</th> <th>lower</th> <th>proven</th> <th>not quantifiable</th> <th>not minor</th> <th>considerable</th> <th>major</th> </tr> </thead> <tbody> <tr> <td></td> <td style="background-color: #cccccc;"></td> <td style="background-color: #cccccc;"></td> <td style="background-color: #cccccc;"></td> <td style="background-color: #cccccc;"></td> <td style="background-color: black;"></td> <td style="background-color: #cccccc;"></td> </tr> </tbody> </table>	Additional benefit (G-BA)	lower	proven	not quantifiable	not minor	considerable	major							
Parameter	Results ¹⁴	HR ¹⁵	p value																																																													
RR ²	10.5 ¹⁹ vs 21.1 ¹⁹		n.s. ¹⁶																																																													
OS ⁵	5.6 vs 9.3	0.64	p < 0.001																																																													
EFS ⁸	0.7 vs 2.8	0.79	n.s. ¹⁶																																																													
Evidence (LoE)	5	4	3b	3a	2c	2b	2a	1b	1a																																																							
Clinical benefit (ESMO MCBS)	1	2	3	4	5																																																											
Additional benefit (G-BA)	lower	proven	not quantifiable	not minor	considerable	major																																																										
<table border="1" style="width: 100%; border-collapse: collapse;"> <tbody> <tr> <td>Patients</td> <td>AML, relapsed/refractory, FLT3mut</td> </tr> <tr> <td>Trial</td> <td>ADMIRAL</td> </tr> <tr> <td>Randomisation</td> <td>2 : 1</td> </tr> <tr> <td>N¹</td> <td>371</td> </tr> <tr> <td>New Therapy</td> <td>Gilteritinib</td> </tr> <tr> <td>Control</td> <td>Chemotherapy</td> </tr> <tr> <td>Publication</td> <td>DOI:10.1056/NEJMoa1902688</td> </tr> </tbody> </table>	Patients	AML, relapsed/refractory, FLT3mut	Trial	ADMIRAL	Randomisation	2 : 1	N¹	371	New Therapy	Gilteritinib	Control	Chemotherapy	Publication	DOI:10.1056/NEJMoa1902688																																																		
Patients	AML, relapsed/refractory, FLT3mut																																																															
Trial	ADMIRAL																																																															
Randomisation	2 : 1																																																															
N¹	371																																																															
New Therapy	Gilteritinib																																																															
Control	Chemotherapy																																																															
Publication	DOI:10.1056/NEJMoa1902688																																																															

Legende:

¹ N - number of patients

² RR - remission rate, in %

⁵ OS - overall survival in months

⁸ EFS - Event-Free Survival

¹⁴ results for control, results for new therapy

¹⁵ hazard ratio for new therapy

¹⁶ n. s. not significant

¹⁹ Complete Remission Rate (CR + CRp)